Charles G Mullighan
Charles G Mullighan is an expert in Hematology at St. Jude Children's Research Hospital (United States). As of October 2026, ScienceLeadR ranks Charles G Mullighan in the top 1% of experts worldwide for Leukemia, Lymphoproliferative Disorders and Lymphoma. Charles G Mullighan has authored 723 publications, the most recent in 2026, and is an investigator in 9 clinical trials. SLR score: 3,467 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Genetics - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Charles Mullighan is a member (Professor) in the Department of Pathology and Senior Deputy Director of the Comprehensive Cancer Center at St Jude Children’s Research Hospital. He trained as a hematologist in Adelaide with doctoral studies in Oxford England, and joined St Jude in 2004. His research program uses integrated genomic analysis, experimental modelling and drug development to define the drivers and vulnerabilities of acute leukemia. His work has defined the genetic basis of multiple new subtypes of leukemia, and these advances have entered the clinic as new diagnostic and therapeutic approaches. He is the recipient of awards including a National Cancer Institute Outstanding Investigator Award, the Meyenburg Prize for Cancer Research, the American Society of Hematology Dameshek Prize, the American Association for Cancer Research – St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research, and election to Fellowship of the Royal Society of London.
Organizations
Career arc: 1993 - 2026
Number : 723
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study. PMID 42832396 — cells, precursor cell lymphoblastic leukemia-lymphoma, leukemia, drug therapy, therapeutics, enhancer elements, genetic, mutation, chemotherapy | Blood | 2026 | 0 |
| Author Correction: Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. PMID 42711487 — histones, lysine | Nature Top journal | 2026 | 0 |
| Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies. PMID 42685004 — cells, precursor cell lymphoblastic leukemia-lymphoma, hematology, neoplasms, leukemia, cell line, polyamines, therapeutics, t-lymphocytes | Blood | 2026 | 0 |
| Mapping the de-implementation of traditional diagnostic tests in pediatric acute lymphoblastic leukemia. PMID 42676406 — precursor cell lymphoblastic leukemia-lymphoma, genomics, neoplasms, leukemia, cytogenetics | Front Oncol | 2026 | 0 |
| Traumatic lumbar puncture at diagnosis in children and adolescents with acute lymphoblastic leukemia. PMID 42538430 — precursor cell lymphoblastic leukemia-lymphoma, spinal puncture, leukemia, adolescent, diagnosis, punctures, child | Leukemia | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map